Archimedes licenses Targit delivery tech to Pharmalink
The deal, financial terms of which were not disclosed, gives Pharmalink exclusive global rights to Archimedes’ Targit technology – which consists of polymer capsules designed to deliver active pharmaceutical ingredients (API) to the lower gastrointestinal tract.
Archimedes will also supply Pharmalink with the manufacturing equipment needed to produce the Targit capsules in-house.
Pharmaklink managing director Johan Haggblad told in-Pharmatechhnologist.com the technology "Is an enteric capsule targeted release formulation system [that] works for our application and is highly reliable.
He added that: "The formulation technology is in transfer and we are in the process of manufacturing clinical trial material [CTM] for coming trials aimed at market authorization."
However, Pharmalink will also continue to work with contractors according to Haggblad who added that: "We are a near-virtual company and set up all product development activities with reputable third party service providers.
"Internally at Pharmalink we focus on driving projects and on deal making."
Collaboration
The firms have worked together on Nefecon – a candidate treatment for the kidney disease IgA nephropathy - since 2004, successfully steering the drug through Phase II trials. The new agreement ends Archimedes' involvement in further development of the medicine.
Archimedes – which was formed when West Pharmaceuticals sold its drug delivery business - retains rights to license Targit to pharmaceutical being developed for other indications and has previously hinted that it could be used in vaccine delivery and inflammatory bowel disease.
Company spokeswoman Julissa Viana told in-Pharmatechnologist.com that: “We have other out-licensing agreements in place using our technologies. The agreement with Pharmalink is just another example of our ongoing strategy to forge partnerships and alliances using our proprietary technologies."
